NCT03250923View on ClinicalTrials.gov

CelAgace™ OraRinse Solution for Treatment of Candidiasis

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

May 31, 2025

Conditions
Candidiasis, Oral
Interventions
DRUG

silver citrate complex and acemannan

Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan

Trial Locations (1)

75246

Texas A&M University College of Dentistry, Dallas

Sponsors
All Listed Sponsors
collaborator

Texas A&M University

OTHER

lead

CelaCare Technologies, Inc.

INDUSTRY